Home  /  Resource Library  /  Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Results of a phase II study of the combination of Ibrutinib, Obinutuzumab and Venetoclax for relpased/refractory CLL.